BioSpace News Archive

Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) (the Company), the company developing new classes of synthetic anti-infectives, is pleased to announce it has recruited 10 healthy male subjects (first cohort) in its Phase I intravenous (IV) clinical trial of its lead compound, RECCE® 327 (R327).

Pharma Two B Ltd., a privately held company developing innovative therapeutics based on reformulation and combinations of previously approved drugs for neurological indications, today announced that its Phase III double-blind, active-controlled study of P2B001 in early Parkinson’s disease (PD) successfully met its primary and key secondary endpoints.

Study successfully met its primary and key secondary endpoints, demonstrating superior efficacy of P2B001 compared to its individual components.

9 Meters Biopharma, Inc. today announced the company has awarded an unrestricted educational grant to Carol Rees Parrish, M.S., RDN, a GI Nutrition Support Specialist to support a new educational website: SBSCurbside.

Cue Biopharma, Inc. announced the appointment of Patricia Nasshorn, as Chief Business Officer, effective December 15th, 2021.

Aerovate Therapeutics, Inc. (Nasdaq: AVTE), today announced the initiation of its Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT) Phase 2b/Phase 3 trial to evaluate the safety and efficacy of AV-101 (dry powder inhaled imatinib) in adult patients with Pulmonary Arterial Hypertension (PAH).

Corcept Therapeutics Incorporated announced an update to its offer to purchase up to 10,000,000 shares of its common stock at a price not greater than $23.75 nor less than $20.75 per share closing at one minute after 11:59 P.M., New York City time, on December 15, 2021.

The first targeted C3 therapy approved in the EU Approval based on results from head-to-head PEGASUS phase 3 study where Aspaveli demonstrated superiority to eculizumab in improving haemoglobin levels 1.

Cybin Inc. ( NEO:CYBN ) ( NYSE American:CYBN) (“ Cybin” or the “ Company” ), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics TM ” today announced that it has been awarded a Notice of Allowance from the U.S. Patent and Trademark Office.

Remix Therapeutics, a biotechnology company developing small molecule therapies designed to reprogram RNA processing and address the underlying drivers of disease, announced the appointment of Zaven Kaprielian, Ph.D., as Chief Scientific Officer.